Sofosbuvir and Daclatasvir Anti–Viral Therapy Fails to Clear HEV Viremia and Restore Reactive T Cells in a HEV/HCV Co-Infected Liver Transplant Recipient

We read with great interest the recently published report ‘Sofosbuvir Inhibits Hepatitis E Virus Replication In Vitro and Results in an Additive Effect When Combined With Ribavirin’ by Dao Thi et al.1 The authors suggest that their important in vitro observations require a clinical proof-of-concept study to confirm that sofosbuvir might be considered as therapy for treatment of chronic hepatitis E.